Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Closes $25M Series B

Premium

Dicerna Pharmaceuticals said that it has closed a $25 million Series B round of financing, which will provide the company with the money needed to advance its lead oncology drug-development program, as well as other pipeline efforts.

Dicerna said it would also use the funds to further develop its delivery technologies.

The round was led by a new investor, Domain Associates, and included existing investors Oxford Bioscience Partners, Skyline Ventures, and Abingworth.

Dicerna first disclosed that it was planning the Series B round to Gene Silencing News in May (GSN 5/13/2010).

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.